The purpose of the study is to see which approach keeps the cancer from getting worse for a longer time, measured as progression‑free survival. Participants receive a series of IV infusions of the two drugs every few weeks, and those in the combination arm also take the lenvatinib capsule each day. Treatment continues for several months, with regular check‑ups that include scans and safety assessments to monitor how the disease is responding and to watch for any side effects.

The main goal of the trial is to learn how safe the medicine is and how well patients can tolerate increasing doses. Participants will receive the drug in a series of treatment cycles that last about four weeks each, with the amount of medicine gradually increased in early groups to find the highest dose that can be given without unacceptable side effects.

During the study, patients will have regular check‑ups, blood tests, and scans to watch for any side effects and to see how the cancer responds. Any problems that arise will be recorded and managed by the medical team, and the study will continue until the predetermined number of treatment cycles is completed or if a participant chooses to stop early.

The study has more than one part. In the first part, small groups of people receive the drug combinations so that researchers can watch for side effects and choose a dose that can be used more widely. In the later part, more people receive the combinations to learn more about how the treatment works in the different cancer groups and to compare dose options in some groups. Because this is an open-label trial, everyone knows which treatment is being given.

During the trial, the treatment is given over time, and participants are followed closely while they are receiving it and for a period afterward. Doctors check for side effects, how well the cancer seems to respond, and how the body handles the drugs. The study includes people with several cancer types, and the treatment plan may differ depending on the cancer group and the study part.

The treatments being studied include belzutifan, which is taken as an oral film-coated tablet, and lenvatinib, which is taken as an oral capsule. Participants in the study will continue their current treatment regimen to monitor how the medications work over a longer period of time. The study will track overall survival, which refers to the length of time patients remain alive, and monitor any adverse events, which are side effects or unexpected medical problems that may occur during the treatment.

People who join this study must have already received at least one dose of RP1, RP2, or RP3 in a previous study and have either finished that study or stopped participating in it. During this study, doctors will watch for specific types of delayed health problems that might be related to the treatment. These include new cancers, new or worsening problems with the nervous system (which controls things like movement and sensation), new or worsening problems with the immune system (which protects the body from disease) or conditions where the immune system attacks the body itself, new blood disorders, new infections related to the treatment, and new infections caused by the herpes virus.

The study will follow patients for several years to collect information about their health and any new medical problems that develop. This helps researchers understand if there are any long-term effects from treatment with these experimental medicines. Patients will be asked to report any new health issues to their doctors, who will record this information as part of the study.

The purpose of the study is to determine the safety and the most effective dosage of these treatments, and to see which combination best shrinks the tumor. Participants will receive their assigned medication through an intravenous infusion, which is a method of delivering medicine directly into a vein. During the study, researchers will monitor how the body reacts to the drugs and how much of the substances remain in the blood.

Participants will receive the medications through intravenous infusion, which means the medicine is delivered directly into a vein. During the study, researchers will monitor how the body processes the drugs and observe any side effects to ensure the treatment is safe. The study will also aim to find the most appropriate dose of PF-08634404 when it is used alongside ipilimumab to best help fight the cancer.

The purpose of the study is to characterize the pharmacokinetics, which describes how a drug moves through the body, specifically for the subcutaneous version of the medicine. Participants will be monitored to ensure the safety of this administration method and to see how much of the medicine stays in the bloodstream over time. During the course of the study, different doses may be used to determine the most appropriate amount for patients.

Participants in the study will receive the medication through an injection or infusion, which can be given into a vein, under the skin, or into a muscle. The study is designed to find the most appropriate dose and to see how the medicine moves through the body. During the course of the study, the way the drug affects the body and its ability to shrink tumors will be monitored. This process involves gradually increasing the amount of medicine given to certain groups to ensure it is safe for use.

The purpose of this study is to compare how the body absorbs different versions of Lenvatinib 10 mg capsules, including two test products and one reference product, when taken both with and without food. The study will measure how much of the medication enters the bloodstream and how long it stays in the body. This is done by looking at the highest level of medication in the blood, when this highest level occurs, and the total amount of medication in the blood over time. The study will also evaluate safety by monitoring any unwanted effects, heart activity through electrical recordings, vital signs like blood pressure and heart rate, and laboratory test results.

The study involves healthy volunteers who will receive single doses of the medication in different treatment periods. Participants will take each version of the capsule at different times, with breaks between treatments, to allow comparison of how each version works in the body. The study design allows each person to receive all three treatments in a specific order, with some participants taking the medication without food and others taking it with food. Blood samples will be collected to measure the levels of medication, and participants will be monitored throughout the study for any changes in their health.

During the study, participants will receive their assigned treatment for up to 36 months. Visugromab and nivolumab will be given through a vein, while lenvatinib will be taken by mouth as capsules. The study will check how the cancer responds to treatment by looking at scans and other tests. Doctors will measure how long it takes before the cancer gets worse and how long people live. They will also check for any side effects from the medicines and ask participants questions about how they are feeling and their quality of life.

Before joining the study, participants must have cancer that can be measured on scans and must have tried one previous treatment that included an anti-PD-(L)1 medicine for at least 12 weeks. Their liver function must be in good condition, and they must have adequate blood counts, kidney function, and other organ functions. The study will monitor participants throughout treatment to track both how well the treatment works and any side effects that may occur.

The purpose of the study is to see how well the combination of these two medications works in preventing the cancer from returning after surgery. The study will also look at how safe these medications are when used together in this way. Patients in this study will receive the medications for a period of time before having surgery to remove the cancer, and then continue receiving the medications after surgery. During the study, doctors will check the cancer using scans and other tests to see if it is shrinking before surgery and to watch for any signs of it coming back after surgery. The total treatment time with the medications can last up to fourteen months.

Throughout the study, doctors will carefully monitor patients for any side effects or problems that might occur from the treatment. They will also collect small samples of the tumor tissue before surgery and during surgery to study how the cancer responds to the medications. Patients will need to have regular check-ups and scans during and after treatment so doctors can measure how well the treatment is working and watch for any signs of the cancer returning.

The main purpose is to determine if adding chemotherapy delivered directly to the liver improves treatment outcomes compared to using only the immune system medications. The study will measure how well tumors respond to treatment and how long patients survive with different treatment approaches.

During the study, participants will receive either the combination of immune system medications alone or together with the liver chemotherapy treatment. The medications will be given through intravenous infusion, while the chemotherapy drugs will be delivered directly into the liver through special tubes. Patients will have regular check-ups to monitor their health and assess how well the treatment is working.

The purpose of this study is to evaluate the effectiveness of combining multiple PET (Positron Emission Tomography) scans into a single imaging session for detecting and determining the stage of these cancers. This approach, called multiplexed imaging, will be compared to traditional single-substance scanning methods.

During the study, participants will receive injections of two different imaging substances through their veins and undergo scanning procedures. The imaging substances are radioactive tracers that help create detailed pictures of areas where cancer might be present in the body. The safety of this combined approach will be monitored, and the quality of the resulting images will be evaluated to determine if this new method provides accurate information about the cancer’s location and extent.

The main purpose of this research is to determine if combining rilvegostomig with tremelimumab and bevacizumab is more effective than using atezolizumab with bevacizumab in treating advanced hepatocellular carcinoma. These medications are given through intravenous infusion, which means they are delivered directly into the bloodstream through a vein.

During the study, patients will be randomly assigned to different treatment groups. One group will receive rilvegostomig together with tremelimumab and bevacizumab, while another group will receive atezolizumab with bevacizumab. The study will monitor how patients respond to these treatments over time, particularly focusing on how long patients survive after starting treatment.

The purpose of the study is to find out the highest concentration of these biotherapy drugs that can be used in skin tests without causing irritation in patients who are not allergic. The study will involve skin tests, such as prick tests and intradermal tests, to check for any allergic reactions. Patients who have been treated with these biotherapies and have not shown any allergic reactions will be part of the study. The study will monitor for any immediate or delayed skin reactions after the tests.

Throughout the study, patients will be contacted to confirm if there are any delayed reactions, which might occur up to a week after the skin tests. If a reaction is suspected, a photograph or video consultation with an allergist may be used to confirm it. The study aims to ensure that the skin tests are safe and do not cause unnecessary irritation to patients undergoing biotherapy treatments.

Participants in the study will undergo the Hyperpolarized [1-13C]pyruvate MRI scan. This involves receiving an injection of the contrast agent through a vein, a process known as intravenous administration. The study will compare the results of these scans to standard imaging methods like MRI and CT scans, which are commonly used to diagnose liver cancer. The goal is to see if the new method can provide more detailed information about the metabolism and blood flow in liver tumors.

The study is designed to last until 2026, with participants being monitored over time to assess the effectiveness of the Hyperpolarized [1-13C]pyruvate MRI in detecting liver cancer early. This research could potentially lead to better ways of diagnosing liver cancer, especially in its early stages, which is crucial for effective treatment. The study does not involve any other diseases or medications, and participants may receive a placebo as part of the trial process.

The purpose of the study is to evaluate the safety and tolerability of CEB-01 when used alongside standard cancer treatments. The study will involve children from birth to under 18 years of age who have these specific types of tumors. Participants will receive the new treatment in addition to their usual care, and the effects will be compared to those who receive only the standard treatment. The study will monitor for any side effects and how well the treatment works in preventing the cancer from coming back or spreading.

Throughout the study, researchers will collect information on the participants’ health and how their bodies process the treatment. This includes measuring the levels of the drug in the blood and observing any changes in the tumors. The study aims to provide valuable information on the potential benefits and risks of using CEB-01 in treating these childhood cancers.

The purpose of this study is to determine how well these medications work together in treating patients with HCC. The study will have different parts: some patients will receive all three medications, while others will receive only NMS-01940153E and Atezolizumab. The study will monitor the patients’ response to the treatment over time, looking at how the cancer responds and how long the response lasts. The study will also assess the safety of the treatment by observing any side effects that may occur.

Participants in the study will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will take place over several months, with regular check-ups to monitor the patients’ health and the progress of the treatment. The goal is to find out if this combination of medications can provide a new treatment option for patients with HCC who have limited options after previous treatments.

The purpose of the study is to evaluate how well the 68Ga-FAPI-46 PET imaging works in detecting gastrointestinal cancers. Participants in the study will undergo this imaging process, which is designed to provide clear pictures of the cancerous regions. The study will compare the results of this new imaging method with previous standard imaging techniques to see if it offers better detection of cancer locations.

Throughout the study, the safety of the 68Ga-FAPI-46 PET imaging will be monitored, including any side effects that may occur. The study will also assess how the imaging results might influence treatment decisions made by doctors. This research aims to improve the understanding of how effective this imaging method is in identifying and managing gastrointestinal cancers.

The purpose of this study is to evaluate different treatment combinations for various risk groups of liver cancer patients. The treatments will be given through infusion into a vein or as tablets, depending on the specific medication. The study will compare different combinations of these medications to find out which ones work best for specific patient groups while monitoring side effects.

Patients will be divided into different groups based on their specific type of liver cancer and risk level. The study will track how well the cancer responds to treatment, how long patients remain free of cancer progression, and overall survival. Throughout the treatment, doctors will closely monitor patients’ heart, kidney, and hearing function, as some of these medications can affect these areas.

The purpose of the study is to evaluate how well the vaccine works in stimulating the immune system, as well as to assess its safety and any potential side effects. Participants in the study will receive the vaccine through an injection under the skin. The study will monitor the participants over time to see how their immune systems respond to the vaccine and to check for any side effects. Some participants may receive additional doses of the vaccine, known as booster shots, to help maintain the immune response.

Throughout the study, researchers will collect information on how the vaccine affects the participants’ health, including any changes in their cancer status and overall quality of life. The study aims to provide valuable insights into the potential benefits of the Fusion-VAC-XS15 vaccine for patients with these specific types of cancer.

The purpose of this study is to evaluate the safety of this combined treatment by monitoring any side effects that may occur. Participants in the study will receive the treatment and be closely observed by medical professionals. The study will track how patients respond to the treatment over time, including any changes in their cancer and overall health. The study aims to provide valuable information on whether this combination of treatments can help patients with HCC who have not had success with other therapies.

Throughout the study, participants will undergo regular check-ups and assessments to ensure their well-being and to gather data on the treatment’s effects. The study will continue until enough information is collected to understand the safety and potential benefits of this new treatment approach. This research is an important step in finding more effective ways to treat liver cancer and improve outcomes for patients.

Participants in the study will receive the treatment as a solution for infusion, which means it will be given through a vein. The study will observe how the treatment affects the cancer and monitor any side effects. The trial will include regular check-ups and assessments to track the progress of the treatment. The study aims to understand how well the treatment works in shrinking the tumors and how safe it is for the patients.

The study will continue for several years, with the goal of gathering enough information to determine the treatment’s effectiveness and safety. This research is important for developing new ways to treat these challenging cancers and could potentially lead to new treatment options for patients in the future.

The purpose of the study is to evaluate how safe this combination of medications is for patients who have had a liver transplant and are dealing with a return of liver cancer. The study will observe patients over a period of six months to see how their bodies respond to the treatment. During this time, the patients will also receive a standard treatment to help prevent their bodies from rejecting the transplanted liver. The study aims to ensure that the treatment does not cause any harmful effects on the liver or the overall health of the patients.

Throughout the study, patients will be monitored regularly to check for any side effects or changes in their condition. This will include regular imaging tests, like CT scans, to track the progress of the cancer and assess the overall health of the patients. The study will also look at how long patients live without the cancer getting worse and how the treatment affects their quality of life. The goal is to gather information that can help improve treatment options for patients with advanced liver cancer who have had a liver transplant.

The purpose of this study is to compare the effects of continuing standard immunotherapy with a reduced dose of the same treatment. The medications being studied include Pembrolizumab, Durvalumab, Avelumab, Nivolumab, Dostarlimab, Atezolizumab, and Cemiplimab. These medications are given through an intravenous infusion, which means they are administered directly into the bloodstream through a vein. Some patients will receive the standard dose of these medications, while others will receive a reduced dose every three months.

The study will last for up to three years, during which time patients will continue to receive their assigned treatment. The main goal is to see if the reduced dose is as effective as the standard dose in keeping the cancer from getting worse. Patients will have regular check-ups and assessments to monitor their health and the progress of their cancer. The study will also look at other factors, such as the quality of life and any side effects experienced by the patients. This research aims to find the best way to use immunotherapy to treat cancer effectively while minimizing side effects.

Participants in the study will receive the treatments over a period of time, with Durvalumab being administered for up to 12 months and Tremelimumab for a shorter duration. The study will monitor the response of the cancer to these treatments, as well as the overall survival and progression of the disease. The study aims to understand how these combined treatments can improve the quality of life and control the disease in patients with non-resectable liver cancer.

Throughout the study, various aspects of the patients’ health will be observed, including how long they live without the cancer getting worse and how the treatments affect their liver function. The study will also assess the time it takes for the cancer to progress to a more advanced stage and how the treatments impact the patients’ overall well-being. The findings from this study could provide valuable insights into new treatment options for liver cancer patients.

The medication being tested, fadraciclib, is taken by mouth in tablet form. It belongs to a group of drugs called CDK2/9 inhibitors, which work by blocking certain proteins that help cancer cells grow. The study aims to find the best dose of the medication and determine how well it works in treating these different types of cancer.

During the study, participants take the medication either once or twice daily in 28-day cycles. The treatment continues as long as it is helping and the side effects are manageable. Throughout the study, doctors monitor the participants’ health and how their cancer responds to the treatment. This includes regular check-ups and various medical tests to ensure safety and track the effectiveness of the medication.

The purpose of this research is to determine how safe the medication is, how it moves through the body, and how effective it is in treating these types of cancer. The study is divided into two parts. In the first part, different doses of the medication will be tested to find the most appropriate amount. In the second part, researchers will evaluate how well the medication works in treating the cancer.

During the study, participants will take CYC140 once daily for 28-day cycles. The treatment will continue as long as it remains beneficial for the patient. Throughout the study, doctors will monitor patients’ health status and how their cancer responds to the treatment. Various medical assessments will be performed to track the progress of the treatment and ensure patient safety.

Participants in the study will receive the treatment through an injection directly into the liver’s blood supply. This method is intended to target the cancer more effectively. The study will last for about 12 months, during which the participants will be monitored regularly to assess the response to the treatment and any side effects. The study aims to see if the cancer can be controlled, meaning it either shrinks, disappears, or remains stable without growing.

Throughout the study, various aspects will be evaluated, such as the time it takes for the treatment to stop working, the length of time participants live without the cancer getting worse, and overall survival. The study will also look at the quality of life of participants and any potential side effects, such as issues with blood vessels in the liver. This information will help determine the effectiveness and safety of the Idarubicin and Lipiodol treatment for people with Hepatocellular Carcinoma.

The treatment involves receiving FMT along with continued administration of atezolizumab and bevacizumab. Atezolizumab works by helping the immune system fight cancer cells, while bevacizumab works by blocking the growth of blood vessels that feed the tumor. Before starting the treatment, patients will need to take medications to clean their bowels, including vancomycin and bowel preparation solutions.

The purpose of this study is to determine whether adding FMT to the existing treatment can help patients whose cancer has worsened within the first four months of their initial therapy. The study will monitor patients for approximately three years to evaluate how well they respond to the treatment and to identify any side effects that may occur.

Participants in the study will receive an injection of a solution containing [18F]PSMA-11, which is a chemical substance known as Gozetotide ALF-18. This substance helps to highlight cancer cells during the imaging process. The study will involve taking images of the liver 60 to 90 minutes after the injection to see how well the cancer can be detected and staged. The study will also look at how long patients live and how long they remain free from cancer progression after the imaging.

The trial will follow participants for up to two years to gather information on survival rates and the effectiveness of the imaging technique. The study aims to provide valuable insights into the use of F-18 PSMA-11 PET/CT for better diagnosis and management of liver cancer, potentially improving outcomes for patients with this condition.

The purpose of this research is to determine how well tislelizumab works in treating liver cancer patients whose liver function is moderately impaired. During the study, participants will receive tislelizumab infusions at regular intervals. The maximum treatment period can last up to 24 months, with patients receiving up to 200 mg of the medication per day.

Throughout the study, patients will have their health monitored through regular medical check-ups and imaging tests to evaluate how their cancer responds to the treatment. The study will also track patients’ overall health status and quality of life during the treatment period. Patients who participate in this research will have their condition monitored for several months after completing the treatment.

Participants in the study will receive the medications durvalumab and tremelimumab through an intravenous infusion, which means the medicine is given directly into a vein. The study will observe the effects of these medications over a period of time to see how the cancer responds. Some participants may also receive a placebo, which is a substance with no active medication, to compare the results. The study aims to understand the anti-tumor activity of the treatment combination within six months.

The trial will monitor the participants’ health and the cancer’s response to the treatment. This includes regular check-ups and tests to ensure the safety and effectiveness of the treatment. The study is designed to help researchers learn more about how these medications can be used to treat HCC and improve outcomes for patients with this condition.

The purpose of this study is to compare the effects of Toripalimab combined with Lenvatinib against a placebo combined with Lenvatinib as the first treatment option for patients with advanced HCC. Participants in the study will be randomly assigned to receive either the combination of Toripalimab and Lenvatinib or the placebo and Lenvatinib. The study will be conducted over a period of time, and participants will receive their treatments through intravenous use for Toripalimab and oral intake for Lenvatinib. The study aims to observe and evaluate the overall survival of patients receiving these treatments.

Throughout the study, participants will be monitored for any side effects or changes in their health. The study will also collect information on how well the treatments work in controlling the cancer and improving the patients’ quality of life. This research is important for understanding how these medications can be used effectively to treat advanced HCC and potentially improve outcomes for patients with this type of cancer.

The purpose of the study is to assess how well patients do without the cancer returning for one year after the ablation procedure. Participants will take Lenvatinib orally, and the study will monitor their progress over time. The trial will also look at how safe the medication is and how well patients respond to the treatment. The study will involve regular check-ups and imaging tests like CT scans or MRI to track the cancer’s response to the treatment.

Throughout the study, researchers will collect samples and data to better understand how the treatment works and to identify any factors that might predict how well a patient responds to Lenvatinib. This information could help improve future treatments for Hepatocellular Carcinoma. The trial is designed to gather valuable insights into the potential benefits and safety of using Lenvatinib in combination with the ablation procedure for treating this type of liver cancer.

The purpose of this study is to determine how well the combination of these medications works in treating this stage of liver cancer and to compare it with the existing treatment method, TACE. Participants in the study will receive either the combination of atezolizumab and bevacizumab or undergo the TACE procedure. The study will monitor various aspects such as the time it takes for the treatment strategy to fail, overall survival rates, and the response of the cancer to the treatment. The study will also look at the safety of the treatments and how they affect the quality of life of the participants.

The trial is expected to run for several years, with an estimated end date in 2027. Participants will be closely monitored throughout the study to assess the effectiveness of the treatments and any potential side effects. The goal is to find a more effective treatment option for patients with this type of liver cancer, potentially improving their outcomes and quality of life.

Participants in the study will receive the treatment through an intravenous infusion, which means the medication is given directly into a vein. The study will monitor how well the treatment is tolerated and its impact on the cancer. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects. The study will also look at how the cancer responds to the treatment, including how long any positive effects last and whether the cancer progresses or not.

Throughout the study, researchers will collect information on any side effects experienced by participants and how the treatment affects their overall health. The study aims to provide valuable insights into the potential benefits and risks of using patritumab deruxtecan for treating these specific types of gastrointestinal cancers. The results will help determine if this treatment could be a viable option for patients in the future.

The purpose of the study is to evaluate how well nivolumab works when used with TACE or TAE in patients with intermediate stage HCC. The study will be conducted in two phases. In the first phase, the focus will be on assessing the effectiveness of the treatment combination. In the second phase, the study will compare the survival rates of patients receiving the combination treatment to those receiving other treatments. Participants will receive the treatments through injections or infusions over a period of time, and their health will be monitored throughout the study.

During the trial, participants will undergo regular assessments to track the progress of their condition and any side effects they may experience. The study aims to provide valuable information on the potential benefits of combining nivolumab with TACE or TAE for treating intermediate stage HCC, ultimately contributing to improved treatment options for patients with this type of liver cancer.

Participants in the study will receive treatment with Durvalumab and Tremelimumab over a period of time before their scheduled surgery. The study will monitor the safety of these medications by observing any side effects that may occur. The treatment period for Durvalumab can last up to 52 weeks, while Tremelimumab is administered over a shorter period of up to 4 weeks. The study will also track any delays in surgery that might be caused by treatment-related side effects.

The trial aims to gather information on how well the treatment works in reducing the size of the tumor and ensuring that the cancer does not return after surgery. Researchers will also collect blood and stool samples for further analysis to understand the effects of the treatment on the immune system and the cancer itself. The study is expected to continue until 2027, with recruitment of participants starting in late 2024.